This clinical trial is focused on studying the effects and safety of a medication called semaglutide in people with early stages of Alzheimer’s disease. Alzheimer’s disease is a condition that affects memory and thinking skills. The study involves participants who have mild cognitive impairment or mild dementia, both of which are early forms of Alzheimer’s disease. The medication being tested is in the form of tablets, known as Rybelsus, which come in different strengths: 3 mg, 7 mg, and 14 mg. Some participants will receive these tablets, while others will receive a placebo, which looks like the medication but does not contain the active ingredient.

The purpose of the study is to determine if semaglutide can improve cognition, which includes memory and thinking abilities, and daily functioning in people with early Alzheimer’s disease. Participants will take the medication or placebo orally, meaning by mouth, over a period of time. The study will monitor changes in their cognitive abilities and daily activities to see if there is any improvement. The trial is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will be regularly assessed to track any changes in their condition. The main focus will be on changes in a specific score that measures dementia symptoms, known as the Clinical Dementia Rating – Sum of Boxes (CDR-SB). Additionally, the study will look at how participants manage daily activities and whether there is any progression to more severe dementia. The trial is expected to continue for a set period, with regular check-ins to evaluate the effects of the treatment.